X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Novo Nordisk gains access to KBP-5074 (ocedurenone), an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for uncontrolled hypertension with potential application in cardiovascular and kidney disease.
Lead Product(s): Ocedurenone
Therapeutic Area: Nephrology Product Name: KBP-5074
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $1,300.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 16, 2023
Details:
KBP-5074 (ocedurenone) is a non-steroidal MRA which selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardioprotective effects.
Lead Product(s): Ocedurenone
Therapeutic Area: Nephrology Product Name: KBP-5074
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
The Phase 2b clinical trial met its primary endpoint, with KBP-5074 demonstrating a clinically and statistically significant improvement in systolic blood pressure (SBP) from baseline to day 84 in Stage 3b/4 CKD patients with uncontrolled hypertension.
Lead Product(s): KBP-5074
Therapeutic Area: Cardiology/Vascular Diseases Product Name: KBP-5074
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
The upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting showcases a pre-clinical study investigating the effect of KBP-5074 on aldosterone-mediated renal injury in the uninephrectomized SD rat CKD model.
Lead Product(s): KBP-5074
Therapeutic Area: Nephrology Product Name: KBP-5074
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Labcorp Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
BLOCK-CKD is a Phase 2b, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of KBP-5074, on top of current therapy, in patients with Stage 3B/4 CKD and uncontrolled hypertension.
Lead Product(s): KBP-5074
Therapeutic Area: Nephrology Product Name: KBP-5074
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Labcorp Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
Single doses of 0.5 mg KBP-5074 were generally well tolerated in patients with severe CKD, with or without hemodialysis . Overall drug exposure was significantly lower in hemodialyzed patients vs. non-hemodialyzed patients.
Lead Product(s): KBP-5074
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Labcorp Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
BLOCK CKD is a randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe CKD and uncontrolled hypertension.
Lead Product(s): KBP-5074
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Labcorp Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
KBP-7072 demonstrated potent activity against geographically-diverse strains of A. baumannii including carbapenem-resistant, colistin-resistant and tetracycline-resistant isolates.
Lead Product(s): KBP-7072
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
